{"id":"NCT03721016","sponsor":"Medy-Tox","briefTitle":"MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-26","primaryCompletion":"2020-03-05","completion":"2021-01-22","firstPosted":"2018-10-26","resultsPosted":"2023-04-21","lastUpdate":"2023-05-25"},"enrollment":415,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Lines","Lateral Canthal Lines"],"interventions":[{"type":"DRUG","name":"MT10109L","otherNames":["NivobotulinumtoxinA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MT10109L Dose 1 + Placebo","type":"EXPERIMENTAL"},{"label":"MT10109L Dose 1 + MT10109L Dose 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.","primaryOutcome":{"measure":"The Percentage of Participants With a â‰¥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS)","timeFrame":"Day 30","effectByArm":[{"arm":"Placebo Into Both Glabellar Lines (GL) and Lateral Canthal Lines (LCL)","deltaMin":0,"sd":null},{"arm":"MT10109L Dose 1 Into Glabellar Lines (GL) + Placebo Into Lateral Canthal Lines (LCL)","deltaMin":78,"sd":null},{"arm":"MT10109L Dose 1 Into Glabellar Lines (GL)+ MT10109L Dose 2 Into Lateral Canthal Lines (LCL)","deltaMin":66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":12},"locations":{"siteCount":21,"countries":["United States","Canada","Germany","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":82},"commonTop":["Headache","Injection site pain"]}}